SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

PrimaryBid.com Offer

20 Jul 2020 16:37

RNS Number : 5356T
Frontier IP Group plc
20 July 2020
 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014.

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF FRONTIER IP GROUP PLC.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN APPROVED BY PRIMARYBID LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN 779021)

20 July 2020

 

Frontier IP Group plc

("Frontier" or the "Company")

PrimaryBid.com Offer

Frontier IP Group plc (AIM:FIPP), the AIM quoted specialist in commercialising intellectual property, is pleased to announce, an offer for subscription via PrimaryBid (the "PrimaryBid Offer") of new ordinary shares of 10p each in the Company ("PrimaryBid Shares") at an issue price of 55 pence per PrimaryBid Share (the "Issue Price"), being a discount of 14.1 per cent to the closing mid-price of the Company's ordinary shares on AIM on 17 July 2020. The Company is also conducting a placing of new ordinary shares (the "Placing Shares") at the Issue Price by way of an accelerated bookbuild process (the "Placing"), as announced by the Company at 4.35pm on 20 July 2020.

The PrimaryBid Offer and the Placing are conditional on, among other things, the PrimaryBid Shares and the Placing Shares being admitted to trading on AIM ("Admission"). Admission is expected to take place at 8.00 a.m. on 27 July 2020. The PrimaryBid Offer will not be completed without the Placing also being completed. 

The Company intends to apply the net proceeds of the PrimaryBid Offer and the Placing, in conjunction with its existing resources, to:

· support the ongoing working capital needs of the business including investment in additional headcount to increase Frontier's capacity to provide commercialisation and development services for portfolio companies; and

· flex the Frontier business model to include both bridge funding and direct participation in investment rounds for portfolio companies to take advantage of existing and future investment opportunities that present themselves, in part due to COVID-19 and its impact on private funding markets.

PrimaryBid Offer

The Company values its retail investor base and is therefore pleased to provide the opportunity to private and other investors to participate in the PrimaryBid Offer by applying exclusively through the www.PrimaryBid.com platform and the PrimaryBid mobile app which is available on Apple's App Store and Google Play. PrimaryBid does not charge investors any commission for this service.

The PrimaryBid Offer, via the PrimaryBid.com platform, will be open to individual and institutional investors from 4:36 p.m. on 20 July 2020 to 9:00 p.m. on 20 July 2020. The PrimaryBid Offer may close early if it is oversubscribed.

Subscriptions under the PrimaryBid Offer will be considered by the Company on a "first come, first served" basis, subject to conditions (which are available to view on PrimaryBid.com).

The Company in consultation with PrimaryBid reserves the right to scale back any order at its discretion. The Company and PrimaryBid reserve the right to reject any application for subscription under the Offer without giving any reason for such rejection.

No commission is charged to investors on applications to participate in the PrimaryBid Offer made through PrimaryBid. It is vital to note that once an application for PrimaryBid Shares has been made and accepted via PrimaryBid, an application cannot be withdrawn.

For further information on PrimaryBid.com or the procedure for applications under the PrimaryBid Offer, visit www.PrimaryBid.com or call PrimaryBid.com on +44 (0) 20 3026 4750. 

The New Ordinary Shares will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rank pari passu in all respects with the Company's existing Ordinary Shares.

Frontier IP Group plc

Neil Crabb, Chief Executive Officer

Andrew Johnson, Communications & Investor Relations

 

+44 (0) 20 7332 2338

PrimaryBid Limited

Kieran D'Silva / James Deal

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / James Hornigold

 

+ 44 (0) 20 3026 4750

 

 

 

+ 44 (0) 20 3328 5656

N+1 Singer (Broker)

+44 (0) 20 7496 3000

Sandy Fraser / Harry Gooden / George Tzimas

 

The Company highly values its retail investor base which has supported the Company alongside institutional investors over several years. Given the longstanding support of retail shareholders, the Company believes that it is appropriate to provide retail and other interested investors the opportunity to participate in the Offer. The Company is therefore making the Offer available exclusively through PrimaryBid.com.

The Offer is offered under the exemptions set out sections 86(1)(e) and 86(4) of the Financial Services and Markets Act 2000 against the need for a prospectus allowed under the Prospectus Regulation Rules. As such, there is no need for publication of a prospectus (and a prospectus will not be published) pursuant to the Prospectus Regulation Rules, or for approval of the same by the Financial Conduct Authority. The Offer is not being made into any jurisdiction where it would be unlawful to do so.

There is a minimum subscription of £100 per investor under the terms of the Offer which is open to existing shareholders and other investors subscribing via PrimaryBid.com. This allocation will be filled on a "first come first served" basis.

For further details please refer to the PrimaryBid.com website at www.PrimaryBid.com. The terms and conditions on which the Offer is made, including the procedure for application and payment for PrimaryBid Shares, is available to all persons who register with PrimaryBid.com.

Investors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.

It should be noted that a subscription for PrimaryBid Shares and investment in the Company carries a number of risks. Investors should consider the risk factors set out on PrimaryBid.com before making a decision to subscribe for PrimaryBid Shares. Investors should take independent advice from a person experienced in advising on investment in securities such as the PrimaryBid Shares if they are in any doubt. 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEPPUGWMUPUGAU
Date   Source Headline
17th Mar 20203:15 pmRNSNotice of interim results
13th Mar 20207:00 amRNSPortfolio news – The Vaccine Group Update
12th Mar 202011:05 amRNSSecond Price Monitoring Extn
12th Mar 202011:00 amRNSPrice Monitoring Extension
19th Feb 202012:37 pmRNSHolding(s) in Company
17th Feb 20207:00 amRNSCRIL wins EUR140,000 EU Graphene Flagship funding
12th Feb 20207:00 amRNSPortfolio news - FIPP increases stake in Celerum
31st Jan 20207:00 amRNSPortfolio news - Exscientia
20th Jan 20207:00 amRNSPortfolio news - The Vaccine Group raises £680,000
16th Jan 20203:28 pmRNSHolding(s) in Company
14th Jan 20207:00 amRNSFieldwork Robotics secures first equity funding
10th Jan 20207:00 amRNSExscientia enters collaboration with Bayer AG
31st Dec 20191:00 pmRNSTotal Voting Rights
16th Dec 201910:36 amRNSExercise of Options and Issue of Equity
11th Dec 20196:03 pmRNSHolding(s) in Company
9th Dec 20193:25 pmRNSHolding(s) in Company
9th Dec 20193:21 pmRNSHolding(s) in Company
9th Dec 20192:08 pmRNSHolding(s) in Company
9th Dec 20199:46 amRNSHolding(s) in Company
9th Dec 20197:00 amRNSGrant of Options
6th Dec 20196:25 pmRNSHolding(s) in Company
5th Dec 201912:00 pmRNSHolding(s) in Company
4th Dec 201912:00 pmRNSResult of AGM & Total Voting Rights
26th Nov 201912:58 pmRNSHolding(s) in Company
13th Nov 20195:00 pmRNSPosting of Annual Report and Accounts
7th Nov 201912:20 pmRNSHolding(s) in Company
6th Nov 20192:00 pmRNSResult of Placing
6th Nov 20197:01 amRNSProposed fundraising of £3.5m by way of Placing
6th Nov 20197:00 amRNSFinal Results
22nd Oct 20197:00 amRNSAppointment of senior advisers
15th Oct 20197:00 amRNSNew portfolio company: Elute Intelligence Holdings
10th Sep 20197:00 amRNSAppointment of Broker
25th Jul 20197:00 amRNSExscientia collaboration with Rallybio
15th Jul 201912:08 pmRNSHolding(s) in Company
14th Jun 20197:00 amRNSExscientia partnership with GT Apeiron
31st May 20195:00 pmRNSTotal Voting Rights
31st May 20193:15 pmRNSDirectorate Change
28th May 20197:00 amRNSFieldwork Robotics completes initial field trials
15th May 20197:00 amRNSDirector exercise of options, shareholding and TVR
10th May 201911:48 amRNSHolding(s) in Company
30th Apr 20197:00 amRNSEuropean plan to boost marine & coastal economies
8th Apr 20197:00 amRNSParkside Architectural Tiles launch Alusid range
8th Apr 20197:00 amRNSInvestor event at the Royal Academy of Engineering
8th Apr 20197:00 amRNSBosch UK to work with Pulsiv Solar
4th Apr 20197:00 amRNSExscientia reaches first major milestone with GSK
3rd Apr 20195:51 pmRNSHolding(s) in Company
3rd Apr 20193:45 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFieldwork Robotics wins Innovate UK ISCF grant
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20191:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.